<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835950</url>
  </required_header>
  <id_info>
    <org_study_id>CLNS01-001 USA</org_study_id>
    <nct_id>NCT02835950</nct_id>
  </id_info>
  <brief_title>TReatment Of Pulmonary HYpertension 1-US Study</brief_title>
  <acronym>TROPHY 1-US</acronym>
  <official_title>Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension - US</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SoniVie Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SoniVie Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, performance and initial effectiveness of
      the TIVUS™ System when used for pulmonary artery denervation through subjective and objective
      change in clinical parameters and haemodynamic evaluation. This is a prospective,
      multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to
      4 centers and will recruit up to 15 patients diagnosed with PAH, functional class III who
      have stable PAH on a stable drug regimen of two pulmonary arterial hypertension specific
      medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of all procedural related adverse event as assessed by the CEC</measure>
    <time_frame>1 month</time_frame>
    <description>Procedural related Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of treatment related adverse event as assessed by the CEC</measure>
    <time_frame>12 month</time_frame>
    <description>All treatment related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patient with PAH worsening and all cause death events</measure>
    <time_frame>12 month</time_frame>
    <description>PAH related adverse events and all cause death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline of mean pulmonary arterial pressure (mPAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline of pulmonary vascular resistance (PVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline of 6 minute walking distance (6MWD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline of quality of life questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>NT-pro-BNP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efffectivness</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Right Ventricular (RV) function as assesed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efffectivness</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in Right Ventricular (RV) function as assesed by Echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Observational Variables</measure>
    <time_frame>12 Months</time_frame>
    <description>Changes from baseline of mean pulmonary arterial pressure (mPAP)</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables</measure>
    <time_frame>12 Months</time_frame>
    <description>Changes from baseline of pulmonary vascular resistance (PVR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables</measure>
    <time_frame>12 Months</time_frame>
    <description>Changes from baseline of 6 minute walking distance (6MWD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables</measure>
    <time_frame>12 Months</time_frame>
    <description>Changes from baseline of quality of life questionaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables - Long term surveillance</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Clinical change of pulmonary arterial hypertension condition defined by patient survival or cause of mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables - Long term surveillance</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Clinical change of pulmonary arterial hypertension condition defined by hospitalization due to pulmonary arterial hypertension</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables - Long term surveillance</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Clinical change of pulmonary arterial hypertension condition defined by any intervention or surgical procedures the patient did</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables - Long term surveillance</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Clinical change of pulmonary arterial hypertension condition defined by worsening of WHO functional class</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables - Long term surveillance</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Clinical change of pulmonary arterial hypertension condition defined by escalation of drug therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Variables</measure>
    <time_frame>12 month</time_frame>
    <description>Echocardiography parameters</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic Intra-Vascular UltraSound (TIVUS™) System</intervention_name>
    <description>The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.
Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.</description>
    <arm_group_label>Pulmonary Denervation</arm_group_label>
    <other_name>TIVUS™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with known pulmonary arterial hypertension (PAH), diagnosed as idiopathic PAH,
             connective tissue disease PAH, Anorexogen induced or Heritable PAH

          -  PAH diagnosis confirmed by hemodynamic evaluation performed prior to screening and
             showing all of the following: Mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest;
             Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure
             (LVEDP) ≤15 mmHg; Pulmonary vascular resistance (PVR) at rest &gt;3 Wood units; Not
             meeting the criteria for a positive vasodilator response (fall in mPAP ≥ 10 mmHg to ≤
             40 mmHg).

          -  Patient with a current diagnosis of WHO functional class III

          -  Patient taking two pulmonary arterial hypertension specific medications other than
             parenteral prostanoids

          -  Patient is adhering to a stable drug regimen (i.e., with no changes of dose or
             medication for a minimum of 3 months prior to enrollment)

          -  Patient with eGFR levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂
             150µmol/l

        Exclusion Criteria:

          -  Patients who are treated with parenteral prostanoids

          -  Pregnant women or women planning a pregnancy within 12 months of study enrolment

          -  Patient with significant co-morbid condition(s) which, at the discretion of the PI,
             are deemed to prohibit study entry

          -  Patient with life expectancy of less than a year

          -  Concurrent enrollment in another device or drug trial except for observational studies
             (unless specifically approved by the sponsor)

          -  Patient with pulmonary artery anatomy that precludes treatment

          -  Patient with moderate to severe pulmonary artery stenosis

          -  Patient with any pulmonary artery aneurysm

          -  Patient who has experienced a myocardial infarction, unstable angina pectoris, or a
             cerebrovascular accident in the previous 6 months

          -  Patient who has implantable cardiac pacemakers, ICDs, neurostimulators, or drug
             infusion devices

          -  Patients who are unable to undergo an MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michal Shohat, DMD</last_name>
    <phone>+972-54-8030015</phone>
    <email>info@sonivie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyong (Nick) Kim, MD</last_name>
      <email>h33kim@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Hyong (Nick) Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vallerie Mclaughlin, MD</last_name>
      <email>vmclaugh@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Vallerie Mclaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Berman-Rosenzweig, MD</last_name>
      <email>esb14@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Erika Berman-Rosenzweig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestren Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Chin, MD</last_name>
      <phone>214-645-5989</phone>
      <email>Kelly.chin@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Chin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

